MEDIA ADVISORY - PRESS CONFERENCE POSTPONED - Media invitation - Treating the heart, helping the brain
A WORLD FIRST: The Montreal Heart Institute to conduct a major clinical study that has the potential to lead to a decrease in the risk of developing cognitive decline, dementia, stroke or TIA
MONTREAL, Nov. 2, 2015 /CNW Telbec/ - The Montreal Heart Institute (MHI) is proud to invite you to the announcement of the BRAIN-AF clinical study in collaboration with the Canadian Stroke Prevention Intervention Network, the pharmaceutical company Bayer, the Montreal Health Innovations Coordinating Center (MHICC), and the MHI Foundation. The clinical study, led by the MHI's team of specialists and researchers and multidisciplinary teams from some thirty Canadian centres, could lead to a decrease in the risk of developing cognitive impairment, stroke or transient ischemic attack (TIA) in patients with atrial fibrillation. This clinical study gives hope to people around the world since, according to the World Health Organization (WHO), 47.5 million people worldwide currently have dementia (severe cognitive impairment).*
What: |
Press conference announcing a world first |
Who: |
Dr. Lena Rivard, researcher, cardiologist and electrophysiologist at the MHI |
When: |
TO BE CONFIRMED |
Where: |
Jean-Parisien Auditorium |
*Source: http://www.who.int/mediacentre/factsheets/fs362/en/
SOURCE Institut de Cardiologie de Montréal
Space is limited, so kindly RSVP by November 3, 2015 to the attention of: Marie-Eve Arsenault, Communication Advisor, Montreal Heart Institute Foundation, Phone: 514-376-3330, extension 2641, [email protected]; Geneviève King-Ruel, Communication Advisor, Montreal Heart Institute, Phone: 514-376-3330, extension 2700, [email protected]
Share this article